UMMC Navigation

Available Trials

Main Content

Gastrointestinal Cancer

For more information regarding these studies, contact Cancer Research and Registry at (601) 984-1095

Colon: Stage III

S0820:A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Colorectal adenomas are tiny growths in the colon that may eventually lead to cancer. The purpose of this study is to determine if eflornithine and sulindac, taken alone or in combination, can decrease the risk of high-risk adenomas or second primary colorectal cancers (a new colorectal cancer developing within the colorectum) in participants who have been treated for Stage 0, I, II, or III colon cancer.

The study drugs eflornithine and sulindac are tablets which are taken orally. Sulindac is approved by the Food and Drug Administration (FDA) for use in rheumatoid arthritis but not for treatment of cancer. Eflornithine is approved by the FDA for other uses but not for treatment of cancer. This means the way we are using these drugs in this study is experimental.

Principal Investigator: Louis Puneky, M.D.

Esophageal (Resectable)

No trials are being conducted for esophageal cancer at UMMC/UMHC.


No trials for pancreatic cancer are being conducted at UMMC/UMHC.


No trials for stomach cancer are being conducted at UMMC/UMHC.


RTOG 1112:Randomized Phase III study of Sorafenib Versus Sterotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma.

The purpose of this study is to compare the effects of sorafenib alone (the present standard of care treatment) with SBRT followed by sorafenib on you and your liver cancer to find out which is better. In this study, you will get either SBRT followed by sorafenib or the sorafenib alone. The standard treatment for hepatocellular carcinoma that is unsuitable for surgery or regional therapy is sorafenib, an oral drug that has been shown to increase the survival of patients compared to no active treatment. Stereotactic body radiation therapy (SBRT), referring to the use of focused high dose radiation generally delivered in 5 or fewer treatment sessions, has also been used to treat hepatocellular carcinoma and has led to tumor shrinkage in many patients.

Principal Investigator: Srinivasan Vijayakumar, M.D